photo.jpg

Something Powerful

Tell The Reader More

The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.

Remember:

  • Bullets are great
  • For spelling out benefits and
  • Turning visitors into leads.

[VIDEO INTERVIEW] Developing Cellular Immunotherapies using Regulatory T Cells

Straight from the Investment for Advanced Therapies hosted by CMS Cameron-McKenna on Wednesday 3rd May, we sat down with Stéphane Boissel, CEO of TxCEll, to find out more about the unique development of their cellular immunotherapies using regulatory T Cells to treat severe inflammatory and autoimmune disease. In this video interview, Stéphane also explains why their CAR Treg platform offers such a rare investment opportunity. Finally, we asked Stéphane what the difficulties and opportunities are in bringing advanced therapies to patients. 

WATCH THE EXCLUSIVE INTERVIEW WITH STEPHANE BOISSEL, CEO OF TXCELL

Investment for Advanced Therapies took place on Wednesday 3rd May and was be the C-Level meeting place for heavyweight investors, analysts, biotechs, venture partners and industry experts who are driving the industry forward. 

TXCELLTxCell is a biotechnology company that develops platforms for innovative, personalized T cell immunotherapies for the treatment of severe inflammatory and autoimmune diseases with high unmet medical need. TxCell targets a wide range of inflammatory diseases (both T-cell and B-cell-mediated) including Crohn’s disease, lupus nephritis, bullous pemphigoid and multiple sclerosis, as well as transplantation-related inflammatory disorders. www.txcell.com

Author Blog
Written By

Add Your Response